| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $25,478 | 5 | 100 |
| Mohideen Pharis | Chief Medical Officer | 0 | $0 | 5 | $25,478 | $-25,478 |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Over the last 12 months, insiders at DBV Technologies S.A. have bought $0 and sold $25,478 worth of DBV Technologies S.A. stock.
On average, over the past 5 years, insiders at DBV Technologies S.A. have bought $29,176 and sold $10,288 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,094 shares for transaction amount of $14,188 was made by Tasse Daniel (CHIEF EXECUTIVE OFFICER) on 2024‑03‑08.
| 2025-11-21 | Sale | Mohideen Pharis | Chief Medical Officer | 1,624 0.0014% | $2.77 | $4,498 | -1.40% | |
| 2025-11-20 | Sale | Mohideen Pharis | Chief Medical Officer | 6,496 0.0057% | $2.88 | $18,708 | -7.24% | |
| 2025-07-29 | Sale | Mohideen Pharis | Chief Medical Officer | 464 0.0004% | $2.22 | $1,030 | +32.50% | |
| 2025-05-22 | Sale | Mohideen Pharis | Chief Medical Officer | 397 0.0003% | $1.84 | $730 | +12.54% | |
| 2025-01-30 | Sale | Mohideen Pharis | Chief Medical Officer | 600 0.0006% | $0.85 | $510 | +123.00% | |
| 2024-11-25 | Sale | Mohideen Pharis | Chief Medical Officer | 565 0.0019% | $0.57 | $322 | +187.70% | |
| 2024-11-22 | Sale | Mohideen Pharis | Chief Medical Officer | 342 0.0011% | $0.53 | $181 | +205.08% | |
| 2024-11-21 | Sale | Mohideen Pharis | Chief Medical Officer | 2,350 0.0074% | $0.54 | $1,269 | +195.08% | |
| 2024-07-29 | Sale | Mohideen Pharis | Chief Medical Officer | 1,785 0.0103% | $0.98 | $1,749 | -15.13% | |
| 2024-05-24 | Sale | Mohideen Pharis | Chief Medical Officer | 660 0.0053% | $1.36 | $898 | -20.16% | |
| 2024-05-22 | Sale | Mohideen Pharis | Chief Medical Officer | 382 0.0031% | $1.38 | $527 | -21.37% | |
| 2024-03-08 | Tasse Daniel | CHIEF EXECUTIVE OFFICER | 17,094 0.0833% | $0.83 | $14,188 | -41.86% | ||
| 2024-02-06 | Ndu Adora | director | 1,825 0.0095% | $0.89 | $1,624 | -39.11% | ||
| 2023-11-22 | Sale | Mohideen Pharis | Chief Medical Officer | 2,245 0.0229% | $1.74 | $3,906 | -23.75% | |
| 2023-08-25 | MORRIS TIMOTHY E | director | 12,000 0.1071% | $1.52 | $18,240 | -46.31% | ||
| 2023-08-01 | SOLAND DANIEL B | director | 15,000 0.1426% | $1.62 | $24,300 | -47.83% | ||
| 2023-05-24 | Sale | Mohideen Pharis | Chief Medical Officer | 469 0.0097% | $3.54 | $1,660 | -51.19% | |
| 2022-11-24 | Sale | Mohideen Pharis | Chief Medical Officer | 1,792 0.0303% | $2.88 | $5,161 | +11.76% |
| Mohideen Pharis | Chief Medical Officer | 101529 0.4244% | $1.83M | 0 | 14 | |
| SOLAND DANIEL B | director | 20000 0.0836% | $359,600.00 | 1 | 0 | <0.0001% |
| Tasse Daniel | CHIEF EXECUTIVE OFFICER | 17094 0.0715% | $307,350.12 | 1 | 0 | <0.0001% |
| MORRIS TIMOTHY E | director | 12000 0.0502% | $215,760.00 | 1 | 0 | <0.0001% |
| Ndu Adora | director | 1825 0.0076% | $32,813.50 | 1 | 0 | <0.0001% |
$22,658,569 | 101 | 1.98% | $399.19M | |
$860,541,348 | 82 | -5.10% | $436.08M | |
$54,836,085 | 68 | -0.52% | $406.01M | |
$17,468,215 | 46 | 18.85% | $456.2M | |
$24,384,691 | 42 | -30.27% | $443.93M | |
$74,231,875 | 30 | 40.62% | $434.55M | |
$54,828,550 | 26 | -13.88% | $429.89M | |
$4,306,464 | 21 | 37.34% | $427.74M | |
$104,137,421 | 15 | 21.28% | $371.2M | |
$65,355,913 | 13 | -3.42% | $392.44M | |
$8,069,667 | 13 | -13.57% | $429.01M | |
$14,995,689 | 8 | 3.76% | $392.97M | |
$43,326,461 | 6 | 16.01% | $379.43M | |
$79,246,559 | 5 | -27.73% | $453.43M | |
$144,224 | 4 | 21.31% | $457.11M | |
DBV Technologies S.A. (DBVT) | $58,352 | 4 | -43.78% | $430.11M |
$1,746,565 | 4 | -29.05% | $450.29M | |
$20,020,000 | 1 | -75.24% | $448.43M | |
$2,248,000 | 1 | -34.10% | $461.67M |
| Increased Positions | 14 | +42.42% | 218,792 | +3.03% |
| Decreased Positions | 10 | -30.3% | 932,145 | -12.89% |
| New Positions | 8 | New | 119,523 | New |
| Sold Out Positions | 4 | Sold Out | 49,654 | Sold Out |
| Total Postitions | 37 | +12.12% | 7M | -9.86% |
| Baker Bros. Advisors Lp | $26,846.00 | 3.65% | 1.46M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $19,371.00 | 2.64% | 1.05M | 0 | 0% | 2025-09-30 |
| Mpm Bioimpact Llc | $19,371.00 | 2.64% | 1.05M | 0 | 0% | 2025-09-30 |
| Octagon Capital Advisors Lp | $18,701.00 | 2.55% | 1.02M | 0 | 0% | 2025-09-30 |
| Yiheng Capital Management, L.P. | $12,056.00 | 1.64% | 656,309 | 0 | 0% | 2025-09-30 |
| Great Point Partners I Lp | $6,955.00 | 0.95% | 378,594 | +3,915 | +1.04% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $6,355.00 | 0.87% | 345,934 | -708,572 | -67.19% | 2025-09-30 |
| Millennium Management Llc | $6,207.00 | 0.85% | 337,863 | +69,849 | +26.06% | 2025-09-30 |
| Artisan Partners Limited Partnership | $954.00 | 0.13% | 51,920 | +51,920 | New | 2025-09-30 |
| Nan Fung Trinity (Hk) Ltd | $681.00 | 0.09% | 37,095 | 0 | 0% | 2025-09-30 |